• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纳入临床病理和肝脏影像报告和数据系统(LI-RADS)基于磁共振成像特征的模型,以识别 LR-M 观察中的肝细胞癌。

A model incorporating clinicopathologic and liver imaging reporting and data system-based magnetic resonance imaging features to identify hepatocellular carcinoma in LR-M observations.

机构信息

Department of Radiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Department of Anesthesiology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

出版信息

Diagn Interv Radiol. 2023 Nov 7;29(6):741-752. doi: 10.4274/dir.2023.232215. Epub 2023 Sep 4.

DOI:10.4274/dir.2023.232215
PMID:37665140
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10679560/
Abstract

PURPOSE

To evaluate the predictive value of a combination model of Liver Imaging Reporting and Data System (LI-RADS)-based magnetic resonance imaging (MRI) and clinicopathologic features to identify atypical hepatocellular carcinoma (HCC) in LI-RADS category M (LR-M) observations.

METHODS

A total of 105 patients with HCC based on surgery or biopsy who underwent preoperative MRI were retrospectively reviewed in the training group from hospital-1 between December 2016 and November 2020. The LI-RADS-based MRI features and clinicopathologic data were compared between LR-M HCC and non-HCC groups. Univariate and least absolute shrinkage and selection operator regression analyses were used to select the features. Binary logistic regression analysis was then conducted to estimate potential predictors of atypical HCC. A predictive nomogram was established based on the combination of MRI and clinicopathologic features and further validated using an independent external set of data from hospital-2.

RESULTS

Of 113 observations from 105 patients (mean age, 61 years; 77 men) in the training set, 47 (41.59%) were classified as LR-M HCC. Following multivariate analysis, aspartate aminotransferase >40 U/L [odds ratio (OR): 4.65], alpha-fetoprotein >20 ng/mL (OR: 13.04), surface retraction (OR: 0.16), enhancing capsule (OR: 5.24), blood products in mass (OR: 8.2), and iso/hypoenhancement on delayed phase (OR: 10.26) were found to be independently correlated with LR-M HCC. The corresponding area under the curve for a combined model-based nomogram was 0.95 in the training patients (n = 113) and 0.90 in the validation cohort (n = 53).

CONCLUSION

The combined model incorporating clinicopathologic and MRI features demonstrated a satisfactory prediction result for LR-M HCC.

摘要

目的

评估基于肝脏影像报告和数据系统(LI-RADS)的磁共振成像(MRI)与临床病理特征相结合的模型对 LI-RADS 类别 M(LR-M)观察中不典型肝细胞癌(HCC)的预测价值。

方法

回顾性分析 2016 年 12 月至 2020 年 11 月在医院 1 接受手术或活检的 105 例 HCC 患者的术前 MRI 资料,将其分为训练组。比较 LR-M HCC 和非 HCC 组的 LI-RADS 基于 MRI 的特征和临床病理数据。采用单因素和最小绝对收缩和选择算子回归分析筛选特征。然后进行二项逻辑回归分析,以评估不典型 HCC 的潜在预测因子。根据 MRI 和临床病理特征建立预测列线图,并在医院 2 的独立外部数据集中进一步验证。

结果

在训练集中,来自 105 例患者的 113 例观察(平均年龄 61 岁,77 例男性)中,47 例(41.59%)被归类为 LR-M HCC。多因素分析后,天门冬氨酸氨基转移酶>40 U/L(比值比(OR):4.65)、甲胎蛋白>20 ng/mL(OR:13.04)、表面回缩(OR:0.16)、增强包膜(OR:5.24)、肿块内血液制品(OR:8.2)和延迟期等/低增强(OR:10.26)与 LR-M HCC 独立相关。在训练患者(n=113)和验证队列(n=53)中,基于联合模型的列线图的曲线下面积分别为 0.95 和 0.90。

结论

包含临床病理和 MRI 特征的联合模型对 LR-M HCC 的预测结果令人满意。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/10679560/8ff9c69385c7/DIR-29-741-g6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/10679560/c06463710d8b/DIR-29-741-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/10679560/df2efcb532f1/DIR-29-741-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/10679560/8a5f1a8bdda4/DIR-29-741-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/10679560/d01a39f5e945/DIR-29-741-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/10679560/a9451f825104/DIR-29-741-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/10679560/8ff9c69385c7/DIR-29-741-g6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/10679560/c06463710d8b/DIR-29-741-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/10679560/df2efcb532f1/DIR-29-741-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/10679560/8a5f1a8bdda4/DIR-29-741-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/10679560/d01a39f5e945/DIR-29-741-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/10679560/a9451f825104/DIR-29-741-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/10679560/8ff9c69385c7/DIR-29-741-g6.jpg

相似文献

1
A model incorporating clinicopathologic and liver imaging reporting and data system-based magnetic resonance imaging features to identify hepatocellular carcinoma in LR-M observations.纳入临床病理和肝脏影像报告和数据系统(LI-RADS)基于磁共振成像特征的模型,以识别 LR-M 观察中的肝细胞癌。
Diagn Interv Radiol. 2023 Nov 7;29(6):741-752. doi: 10.4274/dir.2023.232215. Epub 2023 Sep 4.
2
LR-M Observations on Contrast-Enhanced Ultrasound: Detection of Hepatocellular Carcinoma Using Additional Features in Comparison With Current LI-RADS Criteria.LR-M 超声造影观察:与当前 LI-RADS 标准相比,利用附加特征检测肝细胞癌。
AJR Am J Roentgenol. 2022 Jul;219(1):76-85. doi: 10.2214/AJR.21.26837. Epub 2021 Dec 15.
3
A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions.一种改良的 LI-RADS:具有增强包膜的靶样肿瘤可被诊断为 HCC,而不是 LR-M 病变。
Eur Radiol. 2022 Feb;32(2):912-922. doi: 10.1007/s00330-021-08124-0. Epub 2021 Aug 4.
4
Targetoid hepatic observations on gadoxetic acid-enhanced MRI using LI-RADS version 2018: emphasis on hepatocellular carcinomas assigned to the LR-M category.钆塞酸增强 MRI 下靶征样肝观察:重点关注 LI-RADS 版本 2018 中被归为 LR-M 类的肝细胞癌。
Clin Radiol. 2020 Jun;75(6):478.e13-478.e23. doi: 10.1016/j.crad.2020.01.002. Epub 2020 Feb 5.
5
How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?如何利用 LI-RADS 的 LR-M 特征提高钆塞酸增强 MRI 诊断混合细胞型肝癌?
Eur Radiol. 2019 May;29(5):2408-2416. doi: 10.1007/s00330-018-5893-1. Epub 2018 Dec 14.
6
Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?肝细胞癌:钆塞酸增强磁共振和弥散加权成像的 LI-RADS v2017 能否提高诊断准确性?
World J Gastroenterol. 2019 Feb 7;25(5):622-631. doi: 10.3748/wjg.v25.i5.622.
7
Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.前瞻性应用肝脏成像报告和数据系统(LI-RADS)在钆塞酸增强 MRI 中的诊断准确性。
Eur Radiol. 2018 May;28(5):2038-2046. doi: 10.1007/s00330-017-5188-y. Epub 2017 Dec 11.
8
Liver Imaging Reporting and Data System (LI-RADS) v2018: diagnostic value of ancillary features favoring malignancy in hypervascular observations ≥ 10 mm at intermediate (LR-3) and high probability (LR-4) for hepatocellular carcinoma.肝脏影像报告和数据系统 (LI-RADS) v2018:在中间 (LR-3) 和高概率 (LR-4) 水平下,≥ 10 毫米的富血管性观察中辅助特征有利于肝癌的诊断价值。
Eur Radiol. 2020 Jul;30(7):3770-3781. doi: 10.1007/s00330-020-06698-9. Epub 2020 Feb 27.
9
Contrast-enhanced ultrasound Liver Imaging Reporting and Data System: Lights and shadows in hepatocellular carcinoma and cholangiocellular carcinoma diagnosis.超声造影肝脏影像报告与数据系统:在肝细胞癌和胆管细胞癌诊断中的优缺点。
World J Gastroenterol. 2022 Jul 21;28(27):3488-3502. doi: 10.3748/wjg.v28.i27.3488.
10
Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging.LI-RADS v2018 主要特征和辅助特征的批判性分析在使用钆贝葡胺增强磁共振成像鉴别≤2cm 的小肝癌与异型增生结节中的作用。
Eur Rev Med Pharmacol Sci. 2019 Sep;23(18):7786-7801. doi: 10.26355/eurrev_201909_18988.

引用本文的文献

1
Development and validation of a CT-based nomogram for accurate hepatocellular carcinoma detection in high risk patients.基于CT的列线图在高危患者中准确检测肝细胞癌的开发与验证
Front Oncol. 2024 Aug 6;14:1374373. doi: 10.3389/fonc.2024.1374373. eCollection 2024.

本文引用的文献

1
New strategy for Liver Imaging Reporting and Data System category M to improve diagnostic performance of MRI for hepatocellular carcinoma ≤ 3.0 cm.新策略用于 Liver Imaging Reporting and Data System 类别 M,以提高 MRI 对 ≤ 3.0 厘米肝细胞癌的诊断性能。
Abdom Radiol (NY). 2022 Jul;47(7):2289-2298. doi: 10.1007/s00261-022-03538-w. Epub 2022 May 6.
2
MRI-diagnosis of category LR-M observations in the Liver Imaging Reporting and Data System v2018: a systematic review and meta-analysis.肝脏影像报告和数据系统(LI-RADS)v2018中LR-M类观察结果的MRI诊断:一项系统评价和荟萃分析
Eur Radiol. 2022 May;32(5):3319-3326. doi: 10.1007/s00330-021-08382-y. Epub 2022 Jan 15.
3
Treatment and the prognosis of hepatocellular carcinoma in Asia.
亚洲肝细胞癌的治疗与预后。
Liver Int. 2022 Aug;42(9):2042-2054. doi: 10.1111/liv.15130. Epub 2022 Jan 6.
4
Immunotherapies for hepatocellular carcinoma.肝细胞癌的免疫疗法
Nat Rev Clin Oncol. 2022 Mar;19(3):151-172. doi: 10.1038/s41571-021-00573-2. Epub 2021 Nov 11.
5
A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions.一种改良的 LI-RADS:具有增强包膜的靶样肿瘤可被诊断为 HCC,而不是 LR-M 病变。
Eur Radiol. 2022 Feb;32(2):912-922. doi: 10.1007/s00330-021-08124-0. Epub 2021 Aug 4.
6
Hepatocellular carcinoma.肝细胞癌。
Nat Rev Dis Primers. 2021 Jan 21;7(1):6. doi: 10.1038/s41572-020-00240-3.
7
Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features.钆塞酸增强 MRI 上 LI-RADS M 病变的诊断:通过血清标志物和影像学特征识别含胆管癌的肿瘤。
Eur Radiol. 2021 Jun;31(6):3638-3648. doi: 10.1007/s00330-020-07488-z. Epub 2020 Nov 27.
8
Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?增强超声能区分肝内胆管细胞癌和肝细胞癌吗?
World J Gastroenterol. 2020 Jul 21;26(27):3938-3951. doi: 10.3748/wjg.v26.i27.3938.
9
Liver imaging reporting and data system category M: A systematic review and meta-analysis.肝脏影像报告和数据系统M类:一项系统评价与荟萃分析
Liver Int. 2020 Jun;40(6):1477-1487. doi: 10.1111/liv.14420. Epub 2020 Mar 15.
10
Targetoid hepatic observations on gadoxetic acid-enhanced MRI using LI-RADS version 2018: emphasis on hepatocellular carcinomas assigned to the LR-M category.钆塞酸增强 MRI 下靶征样肝观察:重点关注 LI-RADS 版本 2018 中被归为 LR-M 类的肝细胞癌。
Clin Radiol. 2020 Jun;75(6):478.e13-478.e23. doi: 10.1016/j.crad.2020.01.002. Epub 2020 Feb 5.